QR Pharma Receives US Patent 7,625,942 To Treat Down Syndrome

Main Category: Mental Health
Article Date: 26 Feb 2010 - 2:00 PDT

email to a friend   printer friendly   opinions  

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced that it was issued U.S. Patent No. 7,625,942, a "Method of Treating Down Syndrome" by the U.S. Patent and Trademark Office. The '942 patent covers use of Posiphen and analogs to treat cognitive impairments associated with Down Syndrome (DS). This patent valuably expands upon the original Posiphen and analog patent that claims composition of matter and use of compounds to lower amyloid-β precursor protein (APP) and thereby treat dementia and Alzheimer's disease (AD).

Posiphen, a small orally active compound, has been shown in cell cultures as well as in normal, transgenic (model of AD) and trisomic (model of DS) mice to reduce the synthesis of APP which is cleaved into a number of toxic peptides, including amyloid-β42 (Aβ42). These peptides, independent of each other, attack multiple pathways of neuronal cell life inducing dysfunction, neuronal cell death and inflammation and leading to cognitive impairment.

The chromosome triplicated in DS (chromosome 21 in humans) contains the APP gene, and hence levels of APP are 50% elevated in DS compared to healthy normal people. Indeed, individuals with DS start developing degenerative changes that impair cognitive function in their mid thirties compared to normal people where equivalent changes are seen much later, as in the development of AD.

Trisomic mice treated with Posiphen show preservation of specific brain regions that consistently degenerate without treatment. Posiphen can normalize APP levels and preserve neuronal cells which opens a window for hope in DS, a condition for which there is no available treatment.

"The more we learn about Posiphen the more we see how it interferes with a basic pathway that leads to dementia in DS, AD and likely other conditions, such as head trauma and stroke. Posiphen is presently in a clinical trial in AD patients and we are very hopeful to see the results," said Maria Maccecchini, CEO of QR Pharma.

Source
QR Pharma, Inc.

• Additional
• References
• Citations